Oruka Therapeutics/$ORKA
1D1W1MYTD1Y5YMAX
Capital at risk
About Oruka Therapeutics
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
- Ticker
- $ORKA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Menlo Park, United States
- Website
- orukatx.com
ORKA Metrics
BasicAdvanced
$6.2B
-
-$1.84
-
-
Price and volume
Market cap
$6.2B
52-week high
$115.52
52-week low
$14.89
Average daily volume
769K
Financial strength
Current ratio
38.513
Quick ratio
38.034
Long term debt to equity
0.002
Total debt to equity
0.002
Profitability
EBITDA (TTM)
-154.943
Management effectiveness
Return on assets (TTM)
-12.95%
Return on equity (TTM)
-18.23%
Valuation
Price to book
5.14
Price to tangible book (TTM)
5.14
Price to free cash flow (TTM)
-50.115
Free cash flow yield (TTM)
-2.00%
Free cash flow per share (TTM)
-1.867
Growth
Earnings per share change (TTM)
-5.54%
What the Analysts think about ORKA
Analyst ratings (Buy, Hold, Sell) for Oruka Therapeutics stock.
Analyst projections of the future price of Oruka Therapeutics stock.
Bulls say / Bears say
ORKA-001 achieved a 63.5% PASI 100 rate at Week 16 in the EVERLAST-A Phase 2a trial—surpassing other IL-23p19 inhibitors and driving a premarket share jump—highlighting potential best-in-class efficacy. (Reuters)
As of June 30, 2026, Oruka held $1.1 billion in cash, cash equivalents and marketable securities—providing runway through its anticipated BLA filing for ORKA-001 and lowering near-term financing risk. (SEC Filing)
The pipeline has broadened beyond ORKA-001 with EVERLAST-B now fully enrolled, initiation of ORCA-SPLASH in hidradenitis suppurativa, and ORKA-004 poised to enter the clinic in Q4 2026—ensuring multiple upcoming clinical catalysts. (Oruka Q2 2026 Press Release)
Fairmount Healthcare Fund II sold 3.55 million ORKA shares at $84.43 per share on July 1, 2026—reducing its stake and potentially signaling waning insider confidence in the stock. (SEC Form 4 Filing)
Oruka’s Q2 2026 net loss widened to $41.2 million with R&D expenses rising to $43.3 million—underscoring a high cash burn rate that may strain resources if timelines slip. (Oruka Q2 2026 Press Release)
Key ORKA-002 data from the ORCA-SURGE Phase 2 trial is now expected in Q1 2027, extending the catalyst drought and heightening execution risk for the co-lead program. (Oruka Q2 2026 Press Release)
Data summarised monthly by Lightyear AI. Last updated on 26 Aug 2026.
ORKA Financial Performance
Revenues and expenses
ORKA Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing ORKA
AllUSDGBPEUR
Fund name | Fund size | $ORKA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.38% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.38% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.15% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.05% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.